TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9549662

Group type: EXPERIMENTAL
Intervention: Metrifonate (LD = 1.5 mg/kg, MD = 0.25 mg/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metrifonate (LD = 2.5 mg/kg, MD = 0.40 mg/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metrifonate (LD = 4.0 mg/kg, MD = 0.65 mg/kg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metrifonate (LD = 4.0 mg/kg, MD = 1.0 mg/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Metrifonate (highest doses)
Number of subjects: 27
Study: 8092543

Group type: EXPERIMENTAL
Intervention: Ticlopidine 500 mg/day
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 3381993

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg lidocaine
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: 6 micrograms/kg fentanyl
Number of subjects: 124

Group type: COMPARATOR
Intervention: Thiopental alone
Number of subjects: 124
Study: 30205708

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 149
Study: 27939089

Group type: EXPERIMENTAL
Intervention: Intervention A: 12-session treatment program including discussion of low back pain experience, graded sensory training, graded motor imagery training, and functional movement training.
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Intervention B: 12-session treatment program including discussion of low back pain experience, transcranial direct current stimulation, cranial electrical stimulation, low-intensity laser therapy, and pulsed electromagnetic energy.
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Intervention A and B (both interventions).
Number of subjects: 275
Study: 25534866

Group type: EXPERIMENTAL
Intervention: 40 mg/day simvastatin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/40 mg/day
Number of subjects: 30
Study: 23254319

Group type: EXPERIMENTAL
Intervention: Fluoroscopic screening in patients with recalled Riata leads
Number of subjects: 48
Study: 22088245

Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg/d) plus Irbesartan (150 mg/d)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Felodipine (5 mg/d) plus Metoprolol (47.5 mg/d)
Number of subjects: 123
Study: 17400311

Group type: EXPERIMENTAL
Intervention: Pitavastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 0
Study: 17069060

Group type: EXPERIMENTAL
Intervention: Pronoran
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 12858321

Group type: EXPERIMENTAL
Intervention: 200 mg caffeine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14506194

Group type: EXPERIMENTAL
Intervention: 111In‐ITC‐DTPA‐cG250
Number of subjects: 5

Group type: COMPARATOR
Intervention: 131I‐cG250
Number of subjects: 5
Study: 10202987

Group type: EXPERIMENTAL
Intervention: Sib pairs with MS
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Parent/child pairs with MS
Number of subjects: 51

Group type: COMPARATOR
Intervention: Genomic analysis of TNF loci
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Sib pair analysis using TNF haplotypes
Number of subjects: 51
Study: 7636648

Group type: EXPERIMENTAL
Intervention: DTaP vaccine (booster dose)
Number of subjects: 350
Study: 2794204

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate at 40 meq/L
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate at 100 meq/L
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0 meq/L sodium bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 meq/L sodium bicarbonate
Number of subjects: 0
Study: 797547

Group type: EXPERIMENTAL
Intervention: Halcinonide cream
Number of subjects: 59

Group type: COMPARATOR
Intervention: Fluocinonide cream
Number of subjects: 59
Study: 31685356

Group type: EXPERIMENTAL
Intervention: Early restrictive fluid resuscitation (EFR)
Number of subjects: 174
Study: 28115256

Group type: EXPERIMENTAL
Intervention: Request for Hong Kong Identity Card number (HKID)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: Souvenir incentive (valued at USD4)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: No request for HKID
Number of subjects: 1200

Group type: COMPARATOR
Intervention: No souvenirs
Number of subjects: 1200
Study: 25959848

Group type: EXPERIMENTAL
Intervention: Improved sepsis bundle group (ISBG)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional sepsis bundle group
Number of subjects: 105
Study: 24004682

Group type: EXPERIMENTAL
Intervention: Tailored home hazard reduction and balance and strength exercise fall prevention program
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 22
Study: 21334626

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (nutrition education, exercise therapy, psychological care)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 27

Group type: COMPARATOR
Intervention: Overweight children
Number of subjects: 27
Study: 19724979

Group type: EXPERIMENTAL
Intervention: OXC/TIA
Number of subjects: 56

Group type: COMPARATOR
Intervention: CLO
Number of subjects: 56
Study: 17803010

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15145924

Group type: EXPERIMENTAL
Intervention: Sildenafil (Sil) 3 x 40 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sildenafil (Sil)
Number of subjects: 12
Study: 11759179

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 9510340

Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 480

Group type: COMPARATOR
Intervention: Castration
Number of subjects: 480
Study: 8062500

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (30 mg every 6 hours) with hydrochlorothiazide/amiloride (50 mg/5 mg daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (30 mg every 6 hours) with placebo
Number of subjects: 0
Study: 2897763

Group type: EXPERIMENTAL
Intervention: Ketobemidone + A29 (Ketogan)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 309
Study: 31944251

Group type: EXPERIMENTAL
Intervention: Ankylosing Spondylitis Performed‐Based Improvement (ASPI)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Bath Ankylosing Spondylitis Functional Index (BASFI)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 58
Study: 30562225

Group type: EXPERIMENTAL
Intervention: Local infiltration anaesthesia (LIA) with 150 ml of ropivacaine 0.2% at the end of surgery.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Single-shot sciatic nerve block with 20 ml of ropivacaine 0.75% and adductor canal block with catheter infusion of ropivacaine 0.2% at 6 ml/h for less than 4 days.
Number of subjects: 40
Study: 27472020

Group type: EXPERIMENTAL
Intervention: Badminton
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Running
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 25881510

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 25
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 0
Study: 24040301

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 39
Study: 21415269

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 657

Group type: COMPARATOR
Intervention: No Gemtuzumab ozogamicin (GO)
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin and autologous HCT in favorable-risk AML
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: High-dose daunorubicin and autologous HCT in intermediate-risk AML
Number of subjects: 657
Study: 19171056

Group type: EXPERIMENTAL
Intervention: Manual weaning (PSV manual group)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Automatic weaning (MRV automatic group)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 106
Study: 17299489

Group type: EXPERIMENTAL
Intervention: 0-60 g of retrograded resistant maltodextrins (RRM)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Gradually increasing doses of RRM over 21 days
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: >60 g RRM
Number of subjects: 41
Study: 14734593

Group type: EXPERIMENTAL
Intervention: Ranolazine (750 mg or 1000 mg, twice daily)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 823
Study: 11890236

Group type: EXPERIMENTAL
Intervention: Retroperitoneoscopic ureterolithotomy (RPUL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Open ureterolithotomy
Number of subjects: 55
Study: 9469533

Group type: EXPERIMENTAL
Intervention: Chronic pain patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched healthy controls
Number of subjects: 0
Study: 7940682

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CP)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Azathioprine (AZA)
Number of subjects: 119
Study: 3369332

Group type: EXPERIMENTAL
Intervention: Single-session hypnosis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 60
Study: 31075858

Group type: EXPERIMENTAL
Intervention: Appetitive Pavlovian-to-Instrumental Transfer (PIT) paradigm
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Three-Factor Eating Questionnaire Disinhibition scale
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Individual Restraint scores
Number of subjects: 51
Study: 28286115

Group type: EXPERIMENTAL
Intervention: Augmented renal clearance (ARC) patients receiving β-lactam therapy
Number of subjects: 254

Group type: COMPARATOR
Intervention: Patients without augmented renal clearance (no ARC) receiving β-lactam therapy
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Both ARC and no ARC patients receiving β-lactam therapy
Number of subjects: 254
Study: 25928649

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT) screening
Number of subjects: 0
Study: 23295775

Group type: EXPERIMENTAL
Intervention: Collaborative group intervention (10 weekly group sessions and 2 booster meetings)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Collaborative group intervention
Number of subjects: 304

Group type: COMPARATOR
Intervention: Control condition (pure GP training)
Number of subjects: 304
Study: 21867621

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX) - CF + VDT protocol
Number of subjects: 180
Study: 17420513

Group type: EXPERIMENTAL
Intervention: R‐MCP (mitoxantrone, chlorambucil, prednisolone + rituximab)
Number of subjects: 201

Group type: COMPARATOR
Intervention: MCP (mitoxantrone, chlorambucil, prednisolone)
Number of subjects: 201
Study: 15891590

Group type: EXPERIMENTAL
Intervention: Hologic experimental paediatric protocol for whole body
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Hologic low-density protocol for lumbar spine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Standard adult protocol
Number of subjects: 103
Study: 12173945

Group type: EXPERIMENTAL
Intervention: 6 g;pdd(‐1) of CLA with 3 g;pdd(‐1) of fatty acids for 28 days
Number of subjects: 23

Group type: COMPARATOR
Intervention: 9 g;pdd(‐1) of an olive oil placebo for 28 days
Number of subjects: 23
Study: 9880995

Group type: EXPERIMENTAL
Intervention: Generalized odds-rate class of regression models for time to event data
Number of subjects: 0
Study: 8597965

Group type: EXPERIMENTAL
Intervention: Midazolam 0.2 mg.kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Midazolam 0.4 mg.kg‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Midazolam 0.6 mg.kg‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: NaCl 0.9% (control group)
Number of subjects: 20
Study: 2483443

Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Ibopamine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Dihydroergotoxine
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (non-responders)
Number of subjects: 13
Study: 4820642

Group type: EXPERIMENTAL
Intervention: Heparin and fresh frozen plasma
Number of subjects: 22

Group type: COMPARATOR
Intervention: Fresh frozen plasma alone
Number of subjects: 22
Study: 30280513

Group type: EXPERIMENTAL
Intervention: PEACH™ intervention (6-month family-based weight management programme)
Number of subjects: 169
Study: 27184784

Group type: EXPERIMENTAL
Intervention: TEAM intervention (Pharmacists and pharmacy technicians using novel tools for improving adherence and feedback)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: TEAM intervention
Number of subjects: 576
Study: 25402666

Group type: EXPERIMENTAL
Intervention: Postconditioning
Number of subjects: 72
Study: 22985565

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (5 mg once a year)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (Vitamin D3 and Caltrate daily for a year)
Number of subjects: 48
Study: 20657535

Group type: EXPERIMENTAL
Intervention: MF Afragil®
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 65
Study: 18570599

Group type: EXPERIMENTAL
Intervention: Fexofenadine 180 mg once each morning
Number of subjects: 10

Group type: COMPARATOR
Intervention: Chlorpheniramine 6 mg (2 mg in the morning and 4 mg after 12 h)
Number of subjects: 10
Study: 15912655

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (1,000 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Haemodialysis
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation
Number of subjects: 41
Study: 12478147

Group type: EXPERIMENTAL
Intervention: Re-dosing based on serum testosterone
Number of subjects: 22
Study: 10718909

Group type: EXPERIMENTAL
Intervention: Insulin (0.15 U/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone (125 microg/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vasopressin (0.0143 IU/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Naloxone and vasopressin in combination
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 8
Study: 8794436

Group type: EXPERIMENTAL
Intervention: 1 mg micronized 17 beta‐estradiol continuously
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg micronized 17 beta‐estradiol continuously
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1 mg and 2 mg 17 beta‐estradiol alternating every 42 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined estrogen-progestogen phase
Number of subjects: 30
Study: 1352247

Group type: EXPERIMENTAL
Intervention: Azelastine 2 mg b.d. p.o. for 10 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 6466017

Group type: EXPERIMENTAL
Intervention: Sodium restriction (40 mEq of sodium daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium supplementation to maintain baseline sodium intake (210 mEq/day)
Number of subjects: 0
Study: 30623236

Group type: COMPARATOR
Intervention: IA-HA (2 ml/week, for 3 weeks)
Number of subjects: 120

Group type: COMPARATOR
Intervention: IA-CS (1 ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: IA-PRP (4 ml, 3 times, every 3 weeks)
Number of subjects: 120
Study: 29224460

Group type: EXPERIMENTAL
Intervention: Rocking chair therapy (vestibular stimulation)
Number of subjects: 0
Study: 27132044

Group type: EXPERIMENTAL
Intervention: Citalopram (30mg, oral)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24566573

Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 48

Group type: COMPARATOR
Intervention: NB‐UVB (length: 311 nm)
Number of subjects: 48
Study: 21538084

Group type: EXPERIMENTAL
Intervention: Sexpulse intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 20719303

Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 17614188

Group type: EXPERIMENTAL
Intervention: Tooth mousse (CPP-ACP agent) applied on group A
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tooth mousse (CPP-ACP agent) applied on group C
Number of subjects: 40

Group type: COMPARATOR
Intervention: No agent applied on group B
Number of subjects: 40

Group type: COMPARATOR
Intervention: No agent applied on group D
Number of subjects: 40
Study: 16261661

Group type: EXPERIMENTAL
Intervention: Parenteral polyestradiol phosphate (PEP) therapy (240 mg/month)
Number of subjects: 444

Group type: COMPARATOR
Intervention: Orchiectomy (OE)
Number of subjects: 444
Study: 12016597

Group type: EXPERIMENTAL
Intervention: Preoperative administration of morphine, ketamine, and clonidine (150 microg x kg(‐1) of morphine, 150 microg x kg(‐1) of ketamine, and 5 microg x kg(‐1) of clonidine)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postoperative administration of morphine, ketamine, and clonidine (150 microg x kg(‐1) of morphine, 150 microg x kg(‐1) of ketamine, and 5 microg x kg(‐1) of clonidine)
Number of subjects: 30
Study: 10511390

Group type: EXPERIMENTAL
Intervention: Potassium excretion
Number of subjects: 11629

Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 11629

Group type: EXPERIMENTAL
Intervention: Age, body mass index, alcohol consumption, and pulse rate
Number of subjects: 11629
Study: 8821992

Group type: EXPERIMENTAL
Intervention: 1600 micrograms of inhaled beclomethasone dipropionate (BDP) daily for at least 3 months
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 30 mg of oral prednisolone for 3 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo for 3 weeks
Number of subjects: 21
Study: 1833252

Group type: EXPERIMENTAL
Intervention: Financial counseling
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control group (no financial counseling)
Number of subjects: 115
Study: 6289058

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cimetidine (200 mg three times a day and 400 mg at night)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both ranitidine and cimetidine
Number of subjects: 50
Study: 29644875

Group type: EXPERIMENTAL
Intervention: Gel-200
Number of subjects: 311

Group type: COMPARATOR
Intervention: PBS
Number of subjects: 311
Study: 29181534

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 893
Study: 26437056

Group type: EXPERIMENTAL
Intervention: Low-dose cyclophosphamide 2 g/m2 + G-CSF (arm A)
Number of subjects: 69

Group type: COMPARATOR
Intervention: G-CSF alone (arm B)
Number of subjects: 69
Study: 23916416

Group type: EXPERIMENTAL
Intervention: Icon arrays
Number of subjects: 120

Group type: COMPARATOR
Intervention: Frequencies with icon arrays
Number of subjects: 120

Group type: COMPARATOR
Intervention: Percentages
Number of subjects: 120

Group type: COMPARATOR
Intervention: Frequencies
Number of subjects: 120
Study: 21464679

Group type: EXPERIMENTAL
Intervention: 2-week supply of nicotine patches
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: 4-week supply of nicotine patches
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: 6-week supply of nicotine patches
Number of subjects: 2806

Group type: EXPERIMENTAL
Intervention: Cost per attributable quit
Number of subjects: 2806
Study: 17848939

Group type: EXPERIMENTAL
Intervention: Weight reduction (WR)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study: 17252892

Group type: EXPERIMENTAL
Intervention: Sleep intervention (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (n = 15)
Number of subjects: 30
Study: 12606290

Group type: COMPARATOR
Intervention: Exposure to ethyl benzene (10 and 98 ppm) and 2-butanone (10 and 189 ppm) for 4 hours in experiment I.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Exposure to 2-propanol (35 and 190 ppm) and 1-octanol (0.1 and 6.4 ppm) for 4 hours in experiment II.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both experiments involved exposure to solvents for 4 hours.
Number of subjects: 24
Study: 10848721

Group type: EXPERIMENTAL
Intervention: 3.3% doxepin hydrochloride
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Combination of 3.3% doxepin and 0.025% capsaicin
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 9085951

Group type: EXPERIMENTAL
Intervention: Femoral nerve block (FNB) with 30 mL of 3% alkalinized chloroprocaine
Number of subjects: 68

Group type: COMPARATOR
Intervention: Spinal anesthesia with 65 mg of 5% hyperbaric lidocaine
Number of subjects: 68
Study: 8285849

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate; specific dosage and duration not mentioned
Number of subjects: 0
Study: 3781705

Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg three times daily for three weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30407291

Group type: EXPERIMENTAL
Intervention: Bettercog
Number of subjects: 20

Group type: COMPARATOR
Intervention: COMCOG
Number of subjects: 20
Study: 26784137

Group type: COMPARATOR
Intervention: Palliative care for patients with COPD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palliative care for patients with ILD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Palliative care for patients with COPD and ILD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative care for patients with cancer
Number of subjects: 0
Study: 24809884

Group type: EXPERIMENTAL
Intervention: Body Cream (Eucerin Eczema Relief Body Crème) applied twice daily for 14 days, followed by a 5-day regression period.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instant Therapy (Eucerin Eczema Relief Instant Therapy) for active atopic dermatitis lesions administered for 14 days.
Number of subjects: 0
Study: 22317754

Group type: EXPERIMENTAL
Intervention: internet-based relapse prevention program (RP)
Number of subjects: 258

Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 258
Study: 20300015

Group type: EXPERIMENTAL
Intervention: Nutraceutical blend (EXP; n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Isocaloric equivalent (CON; n = 10)
Number of subjects: 22